1 46 264 A CLINICO-ANALYTICAL STUDY ON SEED OF WRIGHTIA ANTIDYSENTERICA LINN. AS A THERAPEUTIC EMETIC AGENT (VAMAKA YOGA) IN THE MANAGEMENT OF PSORIASIS. OBJECTIVES: WRIGHTIA ANTIDYSENTERICA LINN. (WA) IS MALE VARIETY KUTAJA STATED TO BE POTENT THERAPEUTIC EMETIC AGENT IN SKIN DISORDERS. EXPULSION OF DOSHAS THROUGH ORAL ROUTE IS TERMED AS VAMANA KARMA (VK) (THERAPEUTIC EMESIS). HOWEVER, SO FAR, ITS UTILITY FOR VAMANA IS NOT EXPLORED IN DETAIL, THEREFORE THERE IS A NEED TO REVALIDATE THE UTILITY OF WA FOR VAMANA. HENCE, THE ABOVE STUDY WAS CONDUCTED TO ASCERTAIN THE EFFICACY AS A THERAPEUTIC EMETIC AGENT (VAMAKA YOGA) IN THE MANAGEMENT OF PSORIASIS ALONG WITH QUALITY CONTROL AND STANDARDIZATION OF THIS HERB. MATERIALS AND METHODS: THE DRUG WAS STANDARDIZED AS PER ANALYTICAL PROCEDURES IN PHARMACOPEIAS. THIRTY PATIENTS OF PSORIASIS FULFILLING INCLUSION CRITERIA WERE TAKEN FOR THE STUDY AND VAMANA WITH WA WAS CONDUCTED. CRITERIA WERE PREPARED TO ASSESS THE SIGNS AND SYMPTOMS OF PSORIASIS. VK WAS ASSESSED USING THE CLASSICAL LAKSHANAS (FEATURES) SUCH AS ANTHIKI SHUDHI (ENDING SYMPTOMS OF EMESIS), VAIGIKI SHUDHI (FEATURES OF VOMITING BOUTS), MANIKI SHUDHI (QUANTITATIVE AND QUALITATIVE PURIFICATION), COMPLICATIONS. RESULT: VK WITH WA SHOWED SIGNIFICANT RELIEF IN PARAMETERS OF PSORIASIS SUCH AS SCALING, ITCHING, CANDLE GREASE SIGN (P < 0.001), AND PSORIASIS AREA AND SEVERITY INDEX SCORE (P = 0.001). IN VK WITH WA, MEAN NUMBER OF VEGAS (VOMITING BOUTS) WAS 6.91. 66% PATIENTS SHOWING QUANTITATIVE PURIFICATION BETWEEN 301 AND 600 ML. 73.33% SHOWED ALL SYMPTOMS OF PURIFICATION. 73.33% PATIENTS SHOWED KAPHANTA VAMANA (MODERATE EXPULSION OF DESIRE HUMOR). IN THE LEVEL OF BIOPURIFICATION, 66.66% PATIENTS SHOWED MODERATED PURIFICATION. NO COMPLICATION WAS NOTED WITH MODERATE DRUG PALATABILITY. CONCLUSION: PHARMACOPEIAL ANALYTICAL STUDY SHOWED ITS STANDARDIZED VALUES FOR TESTING THE DRUG USED FOR THE STUDY. IT IS PROVED AS POTENT THERAPEUTIC EMETIC AGENT WITH NO COMPLICATION SHOWED ITS CLINICAL BENEFITS OVER SKIN DISORDER LIKE PSORIASIS. SUMMARY: SEEDS OF WRIGHTIA ANTIDYSENTERICA (WA) LINN. FREE FROM ANY FOREIGN MATTER WERE SELECTED FOR THE STUDY. LOSS ON DRYING REVEALED 6.535% MOISTURE CONTENT; TOTAL ASH INDICATING OF TOTAL INORGANIC CONTENT WAS FOUND TO BE 5.12%; ACID INSOLUBLE ASH IS THE ACID INSOLUBLE PART OF TOTAL ASH, MAINLY SILICA, WA SHOWED 0.393% ACID INSOLUBLE ASH; ETHANOL AND WATER SOLUBLE EXTRACTIVE IS INDICATIVE OF PERCENTAGE ACTIVE CONSTITUENTS WERE FOUND TO BE 25.66 AND 20.854%, RESPECTIVELY. HIGH-PERFORMANCE THIN LAYER CHROMATOGRAPHY FINGERPRINTING PROFILES OF WA UNDER 254 NM SHOWED THE PRESENCE OF 7 SPOTS (ALL IN GREEN) AT RF VALUES RANGING FROM 0.21 TO 0.88. UNDER 366 NM THERE WERE 4 PROMINENT SPOTS (ALL IN FLUORESCENT) AT RF 0.49 TO 0.82 AND, WHEN SCANNED UNDER WHITE LIGHT 620 NM FOLLOWING DERIVATIZATION WITH VANILLIN SULFURIC ACID 6 SPOTS (IN DIFFERENT COLORS) WERE EVIDENT AT RF 0.28 TO 0.58. AMONG THESE SPOT WITH RF OF 0.58 WAS COMMON WHEN VISUALIZED UNDER ALL THE THREE METHODS. RF VALUES BY DENSITOMETRIC SCAN OF WA SHOWED 12 PEAKS AT 254 NM AND 5 PEAKS AT 366 NM. HOWEVER, IN CLINICAL TRIAL, IT WAS FOUND TO BE A POTENT EMETIC AGENT WITHOUT ANY COMPLICATION. ABBREVIATIONS USED: WA: WRIGHTIA ANTIDYSENTERICA; LINN.; VK: VAMANA KARMA; BT: BEFORE TREATMENT; FP: FREIDMAN'S P VALUE; CHS: CHI-SQUARE VALUE; NR: NEGATIVE RANKS; PR: POSITIVE RANKS; N: SAMPLE NUMBER, AS: AUSTIPZ SIGN; CG: CANDLE GREASE TEST; SSL: SAMYAK SNIGDHA LAKSHANA. 2016 2 45 34 A CLINICAL STUDY TO EVALUATE THE EFFICACY OF TRATAKA YOGA KRIYA AND EYE EXERCISES (NON-PHARMOCOLOGICAL METHODS) IN THE MANAGEMENT OF TIMIRA (AMMETROPIA AND PRESBYOPIA). TIMIRA IS A DISEASE THAT CAN BE ATTRIBUTED TO WIDE RANGE OF CLINICAL CONDITIONS STARTING FROM MILD BLURRING OF VISION AND HAVING POTENTIAL RISK OF PERMANENT VISION LOSS. ACCORDING TO THE INVOLVEMENT OF DHATUS (BODY ELEMENTS) THE CONDITION CAN BE GROUPED INTO TWO STAGES. THE INITIAL STAGE OR UTTANA, WHERE THE INVOLVEMENT OF DHATUS IS LIMITED TO RASA, RAKTA (BLOOD), AND MAMSA DHATU (MUSCLE TISSUE). WHEN THE DOSHAS ARE LOCALIZED IN THE FIRST AND SECOND PATALA REFRACTIVE ERROR DO HAPPEN AND IN PRESBYOPIA MORE EMPHASIS IS GIVEN TO MAMSA DHATU. IN THIS STUDY ONLY UTTANA STAGE OF TIMIRA WAS CONSIDERED. THE CLINICAL STUDY WAS DONE ON 66 PATIENTS OF TIMIRA IN TWO GROUPS OF FOUR SUB GROUPS EACH OF MYOPIA, HYPERMETROPIA, ASTIGMATISM, AND PRESBYOPIA. GROUP A WAS SUBJECTED TO EYE EXERCISES (BATES METHOD) AND GROUP B WAS SUBJECTED TO TRATAKA YOGA KRIYA. AFTER THE ENROLMENT OF PATIENTS FOR THIS STUDY, SIGNS AND SYMPTOMS WERE ASSESSED BOTH SUBJECTIVELY AND OBJECTIVELY BEFORE, DURING, AND AFTER TREATMENT. THE STUDY INDICATES THAT SUBJECTIVELY THERE ARE SIGNIFICANT RESULTS IN BOTH THE GROUPS BUT OBJECTIVELY THERE IS NOT MUCH IMPROVEMENT. 2012 3 56 34 A COMPARATIVE STUDY ON THE EFFECTS OF VINTAGE NONPHARMACOLOGICAL TECHNIQUES IN REDUCING MYOPIA (BATES EYE EXERCISE THERAPY VS. TRATAKA YOGA KRIYA). BACKGROUND: HUMAN EYE CAPTURES LIGHT RAYS AS THEY COME AND FALL ON THE RETINA AND CONVERT THEM INTO AN IMAGE. HOWEVER, IN MYOPIA, LIGHT RAYS FALL IN FRONT OF RETINA, CAUSING BLURRING OF IMAGE. CORRECTION OF THIS IS GENERALLY DONE USING CORRECTING DEVICES SUCH AS CORRECTIVE GLASSES AND CONTACT LENSES. EXISTENCE OF SOME ALTERNATIVE THERAPIES IS ALSO NOTICED IN LITERATURE. AIM: TO COMPARE THE EFFECTS OF BATES EYE EXERCISES AND TRATAKA YOGA KRIYA ON MYOPIA. MATERIALS AND METHODOLOGY: ETHICAL CLEARANCE WAS OBTAINED FROM THE INSTITUTION, AND INFORMED CONSENT WAS TAKEN FROM PARTICIPANTS. IN THIS RANDOMIZED COMPARATIVE STUDY, 24 PARTICIPANTS (48 EYES) WERE TAKEN BASED ON INCLUSION AND EXCLUSION CRITERIA AND WERE RANDOMLY DIVIDED INTO TWO GROUPS: GROUP A AND GROUP B, WHERE BATES EYE EXERCISE THERAPY AND TRATAKA YOGA KRIYA WERE GIVEN, RESPECTIVELY, FOR 8 WEEKS. PARTICIPANTS WERE ASSESSED FOR THEIR REFRACTIVE ERRORS AND VISUAL ACUITY PRE- AND POST-INTERVENTION. RESULTS: DATA WERE ANALYZED BY SPSS VERSION 20. RESULTS OBTAINED REVEALED THAT BOTH BATES EXERCISES AND TRATAKA YOGA KRIYA WERE NOT SIGNIFICANTLY EFFECTIVE IN REDUCING REFRACTIVE ERRORS AND IN IMPROVING VISUAL ACUITY (P VALUE OF REFRACTIVE ERROR IN RIGHT EYE: 0.4250; LEFT EYE: 0.4596; P VALUE OF VISUAL ACUITY IN RIGHT EYE: 0.5691; LEFT EYE: 0.8952). CONCLUSION: THIS STUDY CONCLUDES THAT NONPHARMACOLOGICAL APPROACHES SUCH AS EYE EXERCISES AND TRATAKA YOGA KRIYA ARE NOT SIGNIFICANT ON MYOPIA. 2018 4 975 34 EFFECTS OF AN INTEGRATED YOGA PROGRAMME ON CHEMOTHERAPY-INDUCED NAUSEA AND EMESIS IN BREAST CANCER PATIENTS. THIS STUDY EXAMINED THE EFFECT OF AN INTEGRATED YOGA PROGRAMME ON CHEMOTHERAPY-RELATED NAUSEA AND EMESIS IN EARLY OPERABLE BREAST CANCER OUTPATIENTS. SIXTY-TWO SUBJECTS WERE RANDOMLY ALLOCATED TO RECEIVE YOGA (N = 28) OR SUPPORTIVE THERAPY INTERVENTION (N = 34) DURING THE COURSE OF THEIR CHEMOTHERAPY. BOTH GROUPS HAD SIMILAR SOCIO-DEMOGRAPHIC AND MEDICAL CHARACTERISTICS. INTERVENTION CONSISTED OF BOTH SUPERVISED AND HOME PRACTICE OF YOGA SESSIONS LASTING FOR 60 MIN DAILY, WHILE THE CONTROL GROUP RECEIVED SUPPORTIVE THERAPY AND COPING PREPARATION DURING THEIR HOSPITAL VISITS OVER A COMPLETE COURSE OF CHEMOTHERAPY. THE PRIMARY OUTCOME MEASURE WAS THE MORROW ASSESSMENT OF NAUSEA AND EMESIS (MANE) ASSESSED AFTER THE FOURTH CYCLE OF CHEMOTHERAPY. SECONDARY OUTCOMES INCLUDED MEASURES FOR ANXIETY, DEPRESSION, QUALITY OF LIFE, DISTRESSFUL SYMPTOMS AND TREATMENT-RELATED TOXICITY ASSESSED BEFORE AND DURING THE COURSE OF CHEMOTHERAPY. FOLLOWING YOGA, THERE WAS A SIGNIFICANT DECREASE IN POST-CHEMOTHERAPY-INDUCED NAUSEA FREQUENCY (P = 0.01) AND NAUSEA INTENSITY (P = 0.01), AND INTENSITY OF ANTICIPATORY NAUSEA (P = 0.01) AND ANTICIPATORY VOMITING (P = 0.05) AS COMPARED WITH THE CONTROL GROUP. THERE WAS A SIGNIFICANT POSITIVE CORRELATION BETWEEN MANE SCORES AND ANXIETY, DEPRESSION AND DISTRESSFUL SYMPTOMS. IN CONCLUSION, THE RESULTS SUGGEST A POSSIBLE USE FOR STRESS REDUCTION INTERVENTIONS SUCH AS YOGA IN COMPLEMENTING CONVENTIONAL ANTIEMETICS TO MANAGE CHEMOTHERAPY-RELATED NAUSEA AND EMESIS. 2007 5 607 45 DEVELOPMENT OF A CHEWABLE TABLET FROM DUGDHAMALAKYADI YOGA: AN AYURVEDIC PREPARATION. BACKGROUND: AMALAKI (EMBELICA OFFICINALIS GAERTN.) IS ONE OF THE MOST CELEBRATED HERBS IN THE INDIAN SYSTEM OF TRADITIONAL MEDICINE. IT IS ONE OF THE BEST RASAYANA-S (HEALTH PROMOTING) DRUG. IN DUGDHAMALAKYADI YOGA, AMALAKI (EMBELICA OFFICINALIS GAERTN.) POWDER IS ADMINISTERED ALONG WITH MILK IN CASE OF SVARABHANGA (HOARSENESS OF VOICE). HERE AN ATTEMPT IS MADE TO CONVERT THIS FORMULATION INTO CHEWABLE TABLET WITHOUT ALTERING ITS PROPERTY TO IMPROVE ITS PALATABILITY, SHELF LIFE AND FIXATION OF PROPER THERAPEUTIC DOSE. METHODOLOGY: CHEWABLE TABLETS WERE PREPARED BY WET GRANULATION METHOD. HERE, AMALAKI POWDER WAS PREPARED INITIALLY AND IT WAS MIXED WITH ADDITIVES AND PRESERVATIVES. GRANULES WERE PREPARED FROM THIS MIXTURE BY ADDING BINDING AGENT, FINALLY COMPRESSED IN TO TABLETS. RESULTS AND CONCLUSION: THE PHYSICO-CHEMICAL ANALYSIS OF AMALAKI STANDARD ARE: FOREIGN MATTER-NIL, ACID INSOLUBLE ASH-0.51%W/W, WATER SOLUBLE ASH-2.01% W/W, ALCOHOLIC EXTRACTIVES-44.48%, AQUEOUS EXTRACTIVES 67.52%, PH-3.1, MOISTURE CONTENT-8.19%. QUALITY CONTROL TEST FOR CHEWABLE TABLET WAS CARRIED OUT AND FOUND SATISFACTORY WITH GENERAL CHARACTERISTICS OF TABLET VIZ. HARDNESS 1.8, DISINTEGRATION TIME 15-20 MIN, FRIABILITY 0.5%, WEIGHT VARIATION +/- 3%. THE TLC OF AMALAKI POWDER SHOWED 3 SPOTS WITH RF VALUE 0.14, 0.4, AND 0.73 AND THE CHEWABLE TABLETS SHOWED 2 SPOTS WITH RF VALUE 0.31 AND 0.89 UNDER 254 NM. THE ADAPTATION OF MODERN TECHNIQUES OR METHODS TO CONVERT THE AYURVEDIC FORMULATIONS WITHOUT ALTERING ITS THERAPEUTIC PROPERTY IS NECESSARY TO MADE THEM SUITABLE FOR THE PRESENT TRENDS OF NEWER DRUG DELIVERY DOSAGE FORMS. 2012 6 483 53 CLINICAL EFFICACY OF VAMANA KARMA WITH IKSHWAAKU BEEJA YOGA FOLLOWED BY SHATAPUSHPADI GHANAVATI IN THE MANAGEMENT OF ARTAVA KSHAYA W. S. R TO POLYCYSTIC OVARIAN SYNDROME. BACKGROUND: DUE TO SEDENTARY LIFESTYLE AND STRESS, THE INCIDENCE OF METABOLIC DISORDERS ARE INCREASING DAY BY DAY. AMONG THESE POLYCYSTIC OVARIAN SYNDROME (PCOS) IS AN INTRICATE DISORDER AFFECTING 4%-8% WOMEN IN THEIR REPRODUCTIVE AGE AND RELATED TO OVARIAN DYSFUNCTION CHARACTERIZED BY OBESITY, OLIGOMENORRHEA, ANOVULATION AND HYPERANDROGENISM. IN MODERN SYSTEM OF MEDICINE, THE AVAILABLE ALLOPATHIC REGIMEN HAS ITS OWN LIMITATIONS, SO IT IS NEED OF TIME TO FIND A SAFE AND EFFECTIVE ALTERNATIVE THERAPY FOR SUCH TYPE OF CONDITION. THE MOST COMMON SYMPTOM IN 85%-90% OF PCOS PATIENTS IS OLIGOMENORRHEA WHICH CAN BE CORRELATED TO ARTAVA KSHAYA (LOSS OF MENSTRUAL FLUID) IN AYURVEDA. HENCE, IN THE PRESENT CLINICAL STUDY, VAMANA KARMA (THERAPEUTIC VOMITING) WITH IKSHWAAKU SEED FORMULATION FOLLOWED BY SHATAPUSHPADI GHANAVATI WAS PLANNED. AIMS: TO EVALUATE THE EFFICACY OF VAMANA KARMA (THERAPEUTIC VOMITING) FOLLOWED BY SHATAPUSHPADI GHANAVATI IN THE MANAGEMENT OF AARTAVA KSHAYA (LOSS OF MENSTRUAL FLUID) W. S. R TO PCOS. MATERIALS AND METHODS: A TOTAL OF 15 PATIENTS OF PCOS WERE CLINICALLY DIAGNOSED AND TREATED BY VAMANA KARMA (THERAPEUTIC VOMITING) PROCEDURE WITH IKSHWAAKU SEED FORMULATION. AFTER COMPLETION OF VAMANA KARMA (THERAPEUTIC VOMITING) AND SAMSARJANA KRAMA, (POST THERAPY DIETARY REGIMEN FOR REVIVAL) SHATAPUSHPADI GHANAVATI 2 VATI (EACH 500 MG) TWICE IN A DAY WITH LUKEWARM WATER WAS GIVEN FOR 45 DAYS. AFTER COMPLETION OF 2-MONTH TRIAL, ASSESSMENT OF THERAPY WAS ESTIMATED BY SUBJECTIVE AND OBJECTIVE PARAMETERS. RESULTS: STATISTICALLY EXTREMELY SIGNIFICANT (P < 0.0001) RESULTS WERE FOUND IN MENSTRUAL IRREGULARITIES, OBESITY, AND BODY MASS INDEX. THE SIGNIFICANT RESULT IN REDUCTION OF NONDOMINANT FOLLICLES (P = 0.01 AND 0.03 FOR RIGHT AND LEFT OVARY, RESPECTIVELY), LOWERING THE FASTING BLOOD SUGAR LEVEL (P = 0.02) AND HIRSUTISM (P = 0.03) WAS FOUND. CONCLUSION: VAMANA KARMA (THERAPEUTIC VOMITING) FOLLOWED BY SHATAPUSHPADI GHANAVATI IS VERY EFFECTIVE IN THE MANAGEMENT OF OBESE PCOS PATIENTS AND INCREASING CHANCES OF CONCEPTION. 2017 7 2821 59 YOGA TREATMENT FOR CHRONIC NON-SPECIFIC LOW BACK PAIN. BACKGROUND: NON-SPECIFIC LOW BACK PAIN IS A COMMON, POTENTIALLY DISABLING CONDITION USUALLY TREATED WITH SELF-CARE AND NON-PRESCRIPTION MEDICATION. FOR CHRONIC LOW BACK PAIN, CURRENT GUIDELINES STATE THAT EXERCISE THERAPY MAY BE BENEFICIAL. YOGA IS A MIND-BODY EXERCISE SOMETIMES USED FOR NON-SPECIFIC LOW BACK PAIN. OBJECTIVES: TO ASSESS THE EFFECTS OF YOGA FOR TREATING CHRONIC NON-SPECIFIC LOW BACK PAIN, COMPARED TO NO SPECIFIC TREATMENT, A MINIMAL INTERVENTION (E.G. EDUCATION), OR ANOTHER ACTIVE TREATMENT, WITH A FOCUS ON PAIN, FUNCTION, AND ADVERSE EVENTS. SEARCH METHODS: WE SEARCHED CENTRAL, MEDLINE, EMBASE, FIVE OTHER DATABASES AND FOUR TRIALS REGISTERS TO 11 MARCH 2016 WITHOUT RESTRICTION OF LANGUAGE OR PUBLICATION STATUS. WE SCREENED REFERENCE LISTS AND CONTACTED EXPERTS IN THE FIELD TO IDENTIFY ADDITIONAL STUDIES. SELECTION CRITERIA: WE INCLUDED RANDOMIZED CONTROLLED TRIALS OF YOGA TREATMENT IN PEOPLE WITH CHRONIC NON-SPECIFIC LOW BACK PAIN. WE INCLUDED STUDIES COMPARING YOGA TO ANY OTHER INTERVENTION OR TO NO INTERVENTION. WE ALSO INCLUDED STUDIES COMPARING YOGA AS AN ADJUNCT TO OTHER THERAPIES, VERSUS THOSE OTHER THERAPIES ALONE. DATA COLLECTION AND ANALYSIS: TWO AUTHORS INDEPENDENTLY SCREENED AND SELECTED STUDIES, EXTRACTED OUTCOME DATA, AND ASSESSED RISK OF BIAS. WE CONTACTED STUDY AUTHORS TO OBTAIN MISSING OR UNCLEAR INFORMATION. WE EVALUATED THE OVERALL CERTAINTY OF EVIDENCE USING THE GRADE APPROACH. MAIN RESULTS: WE INCLUDED 12 TRIALS (1080 PARTICIPANTS) CARRIED OUT IN THE USA (SEVEN TRIALS), INDIA (THREE TRIALS), AND THE UK (TWO TRIALS). STUDIES WERE UNFUNDED (ONE TRIAL), FUNDED BY A YOGA INSTITUTION (ONE TRIAL), FUNDED BY NON-PROFIT OR GOVERNMENT SOURCES (SEVEN TRIALS), OR DID NOT REPORT ON FUNDING (THREE TRIALS). MOST TRIALS USED IYENGAR, HATHA, OR VINIYOGA FORMS OF YOGA. THE TRIALS COMPARED YOGA TO NO INTERVENTION OR A NON-EXERCISE INTERVENTION SUCH AS EDUCATION (SEVEN TRIALS), AN EXERCISE INTERVENTION (THREE TRIALS), OR BOTH EXERCISE AND NON-EXERCISE INTERVENTIONS (TWO TRIALS). ALL TRIALS WERE AT HIGH RISK OF PERFORMANCE AND DETECTION BIAS BECAUSE PARTICIPANTS AND PROVIDERS WERE NOT BLINDED TO TREATMENT ASSIGNMENT, AND OUTCOMES WERE SELF-ASSESSED. THEREFORE, WE DOWNGRADED ALL OUTCOMES TO 'MODERATE' CERTAINTY EVIDENCE BECAUSE OF RISK OF BIAS, AND WHEN THERE WAS ADDITIONAL SERIOUS RISK OF BIAS, UNEXPLAINED HETEROGENEITY BETWEEN STUDIES, OR THE ANALYSES WERE IMPRECISE, WE DOWNGRADED THE CERTAINTY OF THE EVIDENCE FURTHER.FOR YOGA COMPARED TO NON-EXERCISE CONTROLS (9 TRIALS; 810 PARTICIPANTS), THERE WAS LOW-CERTAINTY EVIDENCE THAT YOGA PRODUCED SMALL TO MODERATE IMPROVEMENTS IN BACK-RELATED FUNCTION AT THREE TO FOUR MONTHS (STANDARDIZED MEAN DIFFERENCE (SMD) -0.40, 95% CONFIDENCE INTERVAL (CI) -0.66 TO -0.14; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MEAN DIFFERENCE (MD) -2.18, 95% -3.60 TO -0.76), MODERATE-CERTAINTY EVIDENCE FOR SMALL TO MODERATE IMPROVEMENTS AT SIX MONTHS (SMD -0.44, 95% CI -0.66 TO -0.22; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD -2.15, 95% -3.23 TO -1.08), AND LOW-CERTAINTY EVIDENCE FOR SMALL IMPROVEMENTS AT 12 MONTHS (SMD -0.26, 95% CI -0.46 TO -0.05; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD -1.36, 95% -2.41 TO -0.26). ON A 0-100 SCALE THERE WAS VERY LOW- TO MODERATE-CERTAINTY EVIDENCE THAT YOGA WAS SLIGHTLY BETTER FOR PAIN AT THREE TO FOUR MONTHS (MD -4.55, 95% CI -7.04 TO -2.06), SIX MONTHS (MD -7.81, 95% CI -13.37 TO -2.25), AND 12 MONTHS (MD -5.40, 95% CI -14.50 TO -3.70), HOWEVER WE PRE-DEFINED CLINICALLY SIGNIFICANT CHANGES IN PAIN AS 15 POINTS OR GREATER AND THIS THRESHOLD WAS NOT MET. BASED ON INFORMATION FROM SIX TRIALS, THERE WAS MODERATE-CERTAINTY EVIDENCE THAT THE RISK OF ADVERSE EVENTS, PRIMARILY INCREASED BACK PAIN, WAS HIGHER IN YOGA THAN IN NON-EXERCISE CONTROLS (RISK DIFFERENCE (RD) 5%, 95% CI 2% TO 8%).FOR YOGA COMPARED TO NON-YOGA EXERCISE CONTROLS (4 TRIALS; 394 PARTICIPANTS), THERE WAS VERY-LOW-CERTAINTY EVIDENCE FOR LITTLE OR NO DIFFERENCE IN BACK-RELATED FUNCTION AT THREE MONTHS (SMD -0.22, 95% CI -0.65 TO 0.20; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD -0.99, 95% -2.87 TO 0.90) AND SIX MONTHS (SMD -0.20, 95% CI -0.59 TO 0.19; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD -0.90, 95% -2.61 TO 0.81), AND NO INFORMATION ON BACK-RELATED FUNCTION AFTER SIX MONTHS. THERE WAS VERY LOW-CERTAINTY EVIDENCE FOR LOWER PAIN ON A 0-100 SCALE AT SEVEN MONTHS (MD -20.40, 95% CI -25.48 TO -15.32), AND NO INFORMATION ON PAIN AT THREE MONTHS OR AFTER SEVEN MONTHS. BASED ON INFORMATION FROM THREE TRIALS, THERE WAS LOW-CERTAINTY EVIDENCE FOR NO DIFFERENCE IN THE RISK OF ADVERSE EVENTS BETWEEN YOGA AND NON-YOGA EXERCISE CONTROLS (RD 1%, 95% CI -4% TO 6%).FOR YOGA ADDED TO EXERCISE COMPARED TO EXERCISE ALONE (1 TRIAL; 24 PARTICIPANTS), THERE WAS VERY-LOW-CERTAINTY EVIDENCE FOR LITTLE OR NO DIFFERENCE AT 10 WEEKS IN BACK-RELATED FUNCTION (SMD -0.60, 95% CI -1.42 TO 0.22; CORRESPONDING TO A CHANGE IN THE OSWESTRY DISABILITY INDEX OF MD -17.05, 95% -22.96 TO 11.14) OR PAIN ON A 0-100 SCALE (MD -3.20, 95% CI -13.76 TO 7.36). THERE WAS NO INFORMATION ON OUTCOMES AT OTHER TIME POINTS. THERE WAS NO INFORMATION ON ADVERSE EVENTS.STUDIES PROVIDED LIMITED EVIDENCE ON RISK OF CLINICAL IMPROVEMENT, MEASURES OF QUALITY OF LIFE, AND DEPRESSION. THERE WAS NO EVIDENCE ON WORK-RELATED DISABILITY. AUTHORS' CONCLUSIONS: THERE IS LOW- TO MODERATE-CERTAINTY EVIDENCE THAT YOGA COMPARED TO NON-EXERCISE CONTROLS RESULTS IN SMALL TO MODERATE IMPROVEMENTS IN BACK-RELATED FUNCTION AT THREE AND SIX MONTHS. YOGA MAY ALSO BE SLIGHTLY MORE EFFECTIVE FOR PAIN AT THREE AND SIX MONTHS, HOWEVER THE EFFECT SIZE DID NOT MEET PREDEFINED LEVELS OF MINIMUM CLINICAL IMPORTANCE. IT IS UNCERTAIN WHETHER THERE IS ANY DIFFERENCE BETWEEN YOGA AND OTHER EXERCISE FOR BACK-RELATED FUNCTION OR PAIN, OR WHETHER YOGA ADDED TO EXERCISE IS MORE EFFECTIVE THAN EXERCISE ALONE. YOGA IS ASSOCIATED WITH MORE ADVERSE EVENTS THAN NON-EXERCISE CONTROLS, BUT MAY HAVE THE SAME RISK OF ADVERSE EVENTS AS OTHER BACK-FOCUSED EXERCISE. YOGA IS NOT ASSOCIATED WITH SERIOUS ADVERSE EVENTS. THERE IS A NEED FOR ADDITIONAL HIGH-QUALITY RESEARCH TO IMPROVE CONFIDENCE IN ESTIMATES OF EFFECT, TO EVALUATE LONG-TERM OUTCOMES, AND TO PROVIDE ADDITIONAL INFORMATION ON COMPARISONS BETWEEN YOGA AND OTHER EXERCISE FOR CHRONIC NON-SPECIFIC LOW BACK PAIN. 2017 8 2543 57 YOGA FOR ASTHMA. BACKGROUND: ASTHMA IS A COMMON CHRONIC INFLAMMATORY DISORDER AFFECTING ABOUT 300 MILLION PEOPLE WORLDWIDE. AS A HOLISTIC THERAPY, YOGA HAS THE POTENTIAL TO RELIEVE BOTH THE PHYSICAL AND PSYCHOLOGICAL SUFFERING OF PEOPLE WITH ASTHMA, AND ITS POPULARITY HAS EXPANDED GLOBALLY. A NUMBER OF CLINICAL TRIALS HAVE BEEN CARRIED OUT TO EVALUATE THE EFFECTS OF YOGA PRACTICE, WITH INCONSISTENT RESULTS. OBJECTIVES: TO ASSESS THE EFFECTS OF YOGA IN PEOPLE WITH ASTHMA. SEARCH METHODS: WE SYSTEMATICALLY SEARCHED THE COCHRANE AIRWAYS GROUP REGISTER OF TRIALS, WHICH IS DERIVED FROM SYSTEMATIC SEARCHES OF BIBLIOGRAPHIC DATABASES INCLUDING THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, AND PSYCINFO, AND HANDSEARCHING OF RESPIRATORY JOURNALS AND MEETING ABSTRACTS. WE ALSO SEARCHED PEDRO. WE SEARCHED CLINICALTRIALS.GOV AND THE WHO ICTRP SEARCH PORTAL. WE SEARCHED ALL DATABASES FROM THEIR INCEPTION TO 22 JULY 2015, AND USED NO RESTRICTION ON LANGUAGE OF PUBLICATION. WE CHECKED THE REFERENCE LISTS OF ELIGIBLE STUDIES AND RELEVANT REVIEW ARTICLES FOR ADDITIONAL STUDIES. WE ATTEMPTED TO CONTACT INVESTIGATORS OF ELIGIBLE STUDIES AND EXPERTS IN THE FIELD TO LEARN OF OTHER PUBLISHED AND UNPUBLISHED STUDIES. SELECTION CRITERIA: WE INCLUDED RANDOMISED CONTROLLED TRIALS (RCTS) THAT COMPARED YOGA WITH USUAL CARE (OR NO INTERVENTION) OR SHAM INTERVENTION IN PEOPLE WITH ASTHMA AND REPORTED AT LEAST ONE OF THE FOLLOWING OUTCOMES: QUALITY OF LIFE, ASTHMA SYMPTOM SCORE, ASTHMA CONTROL, LUNG FUNCTION MEASURES, ASTHMA MEDICATION USAGE, AND ADVERSE EVENTS. DATA COLLECTION AND ANALYSIS: WE EXTRACTED BIBLIOGRAPHIC INFORMATION, CHARACTERISTICS OF PARTICIPANTS, CHARACTERISTICS OF INTERVENTIONS AND CONTROLS, CHARACTERISTICS OF METHODOLOGY, AND RESULTS FOR THE OUTCOMES OF OUR INTEREST FROM ELIGIBLE STUDIES. FOR CONTINUOUS OUTCOMES, WE USED MEAN DIFFERENCE (MD) WITH 95% CONFIDENCE INTERVAL (CI) TO DENOTE THE TREATMENT EFFECTS, IF THE OUTCOMES WERE MEASURED BY THE SAME SCALE ACROSS STUDIES. ALTERNATIVELY, IF THE OUTCOMES WERE MEASURED BY DIFFERENT SCALES ACROSS STUDIES, WE USED STANDARDISED MEAN DIFFERENCE (SMD) WITH 95% CI. FOR DICHOTOMOUS OUTCOMES, WE USED RISK RATIO (RR) WITH 95% CI TO MEASURE THE TREATMENT EFFECTS. WE PERFORMED META-ANALYSIS WITH REVIEW MANAGER 5.3. WE USED THE FIXED-EFFECT MODEL TO POOL THE DATA, UNLESS THERE WAS SUBSTANTIAL HETEROGENEITY AMONG STUDIES, IN WHICH CASE WE USED THE RANDOM-EFFECTS MODEL INSTEAD. FOR OUTCOMES INAPPROPRIATE OR IMPOSSIBLE TO POOL QUANTITATIVELY, WE CONDUCTED A DESCRIPTIVE ANALYSIS AND SUMMARISED THE FINDINGS NARRATIVELY. MAIN RESULTS: WE INCLUDED 15 RCTS WITH A TOTAL OF 1048 PARTICIPANTS. MOST OF THE TRIALS WERE CONDUCTED IN INDIA, FOLLOWED BY EUROPE AND THE UNITED STATES. THE MAJORITY OF PARTICIPANTS WERE ADULTS OF BOTH SEXES WITH MILD TO MODERATE ASTHMA FOR SIX MONTHS TO MORE THAN 23 YEARS. FIVE STUDIES INCLUDED YOGA BREATHING ALONE, WHILE THE OTHER STUDIES ASSESSED YOGA INTERVENTIONS THAT INCLUDED BREATHING, POSTURE, AND MEDITATION. INTERVENTIONS LASTED FROM TWO WEEKS TO 54 MONTHS, FOR NO MORE THAN SIX MONTHS IN THE MAJORITY OF STUDIES. THE RISK OF BIAS WAS LOW ACROSS ALL DOMAINS IN ONE STUDY AND UNCLEAR OR HIGH IN AT LEAST ONE DOMAIN FOR THE REMAINDER.THERE WAS SOME EVIDENCE THAT YOGA MAY IMPROVE QUALITY OF LIFE (MD IN ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) SCORE PER ITEM 0.57 UNITS ON A 7-POINT SCALE, 95% CI 0.37 TO 0.77; 5 STUDIES; 375 PARTICIPANTS), IMPROVE SYMPTOMS (SMD 0.37, 95% CI 0.09 TO 0.65; 3 STUDIES; 243 PARTICIPANTS), AND REDUCE MEDICATION USAGE (RR 5.35, 95% CI 1.29 TO 22.11; 2 STUDIES) IN PEOPLE WITH ASTHMA. THE MD FOR AQLQ SCORE EXCEEDED THE MINIMAL CLINICALLY IMPORTANT DIFFERENCE (MCID) OF 0.5, BUT WHETHER THE MEAN CHANGES EXCEEDED THE MCID FOR ASTHMA SYMPTOMS IS UNCERTAIN DUE TO THE LACK OF AN ESTABLISHED MCID IN THE SEVERITY SCORES USED IN THE INCLUDED STUDIES. THE EFFECTS OF YOGA ON CHANGE FROM BASELINE FORCED EXPIRATORY VOLUME IN ONE SECOND (MD 0.04 LITRES, 95% CI -0.10 TO 0.19; 7 STUDIES; 340 PARTICIPANTS; I(2) = 68%) WERE NOT STATISTICALLY SIGNIFICANT. TWO STUDIES INDICATED IMPROVED ASTHMA CONTROL, BUT DUE TO VERY SIGNIFICANT HETEROGENEITY (I(2) = 98%) WE DID NOT POOL DATA. NO SERIOUS ADVERSE EVENTS ASSOCIATED WITH YOGA WERE REPORTED, BUT THE DATA ON THIS OUTCOME WAS LIMITED. AUTHORS' CONCLUSIONS: WE FOUND MODERATE-QUALITY EVIDENCE THAT YOGA PROBABLY LEADS TO SMALL IMPROVEMENTS IN QUALITY OF LIFE AND SYMPTOMS IN PEOPLE WITH ASTHMA. THERE IS MORE UNCERTAINTY ABOUT POTENTIAL ADVERSE EFFECTS OF YOGA AND ITS IMPACT ON LUNG FUNCTION AND MEDICATION USAGE. RCTS WITH A LARGE SAMPLE SIZE AND HIGH METHODOLOGICAL AND REPORTING QUALITY ARE NEEDED TO CONFIRM THE EFFECTS OF YOGA FOR ASTHMA. 2016 9 2657 59 YOGA IN ADDITION TO STANDARD CARE FOR PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES. BACKGROUND: HAEMATOLOGICAL MALIGNANCIES ARE MALIGNANT NEOPLASMS OF THE MYELOID OR LYMPHATIC CELL LINES INCLUDING LEUKAEMIA, LYMPHOMA AND MYELOMA. IN ORDER TO MANAGE PHYSICAL AND PSYCHOLOGICAL ASPECTS OF THE DISEASE AND ITS TREATMENT, COMPLEMENTARY THERAPIES LIKE YOGA ARE COMING INCREASINGLY INTO FOCUS. HOWEVER, THE EFFECTIVENESS OF YOGA PRACTICE FOR PEOPLE SUFFERING FROM HAEMATOLOGICAL MALIGNANCIES REMAINS UNCLEAR. OBJECTIVES: TO ASSESS THE EFFECTS OF YOGA PRACTICE IN ADDITION TO STANDARD CANCER TREATMENT FOR PEOPLE WITH HAEMATOLOGICAL MALIGNANCIES. SEARCH METHODS: OUR SEARCH STRATEGY INCLUDED THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS (CENTRAL), MEDLINE (1950 TO 4TH FEBRUARY 2014), DATABASES OF ONGOING TRIALS (CONTROLLED-TRIALS.COM; CLINICALTRIALS.GOV), CONFERENCE PROCEEDINGS OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY, THE AMERICAN SOCIETY OF HEMATOLOGY, THE EUROPEAN HAEMATOLOGY ASSOCIATION, THE EUROPEAN CONGRESS FOR INTEGRATIVE MEDICINE, AND GLOBAL ADVANCES IN HEALTH AND MEDICINE. WE HANDSEARCHED REFERENCES OF THESE STUDIES FROM IDENTIFIED TRIALS AND RELEVANT REVIEW ARTICLES. TWO REVIEW AUTHORS INDEPENDENTLY SCREENED THE SEARCH RESULTS. SELECTION CRITERIA: WE INCLUDED RANDOMISED CONTROLLED TRIALS (RCTS) OF YOGA IN ADDITION TO STANDARD CARE FOR HAEMATOLOGICAL MALIGNANCIES COMPARED WITH STANDARD CARE ONLY. WE DID NOT RESTRICT THIS TO ANY SPECIFIC STYLE OF YOGA. DATA COLLECTION AND ANALYSIS: TWO REVIEW AUTHORS INDEPENDENTLY EXTRACTED DATA FOR ELIGIBLE STUDIES AND ASSESSED THE RISK OF BIAS ACCORDING TO PREDEFINED CRITERIA. WE EVALUATED DISTRESS, FATIGUE, ANXIETY, DEPRESSION AND QUALITY OF SLEEP. FURTHER OUTCOMES WE PLANNED TO ASSESS WERE HEALTH-RELATED QUALITY OF LIFE (HRQOL), OVERALL SURVIVAL (OS) AND ADVERSE EVENTS (AE), BUT DATA ON THESE WERE NOT AVAILABLE. MAIN RESULTS: OUR SEARCH STRATEGIES LED TO 149 POTENTIALLY RELEVANT REFERENCES, BUT ONLY A SINGLE SMALL STUDY MET OUR INCLUSION CRITERIA. THE INCLUDED STUDY WAS PUBLISHED AS A FULL TEXT ARTICLE AND INVESTIGATED THE FEASIBILITY AND EFFECT OF TIBETAN YOGA ADDITIONAL TO STANDARD CARE (N = 20; 1 PERSON DROPPED OUT BEFORE ATTENDING ANY CLASSES AND NO DATA WERE COLLECTED) COMPARED TO STANDARD CARE ONLY (N = 19). THE STUDY INCLUDED PEOPLE WITH ALL STAGES OF HODGKIN AND NON-HODGKIN'S LYMPHOMA, WITH AND WITHOUT CURRENT CANCER TREATMENT. THE MEAN AGE WAS 51 YEARS.WE JUDGED THE OVERALL RISK OF BIAS AS HIGH AS WE FOUND A HIGH RISK FOR PERFORMANCE, DETECTION AND ATTRITION BIAS. ADDITIONALLY, POTENTIAL OUTCOME REPORTING BIAS COULD NOT BE COMPLETELY RULED OUT. FOLLOWING THE RECOMMENDATIONS OF GRADE, WE JUDGED THE OVERALL QUALITY OF THE BODY OF EVIDENCE FOR ALL PREDEFINED OUTCOMES AS 'VERY LOW', DUE TO THE METHODICAL LIMITATIONS AND THE VERY SMALL SAMPLE SIZE.THE INFLUENCE OF YOGA ON HRQOL AND OS WAS NOT REPORTED. THERE IS NO EVIDENCE THAT YOGA IN ADDITION TO STANDARD CARE COMPARED WITH STANDARD CARE ONLY CAN IMPROVE DISTRESS IN PEOPLE WITH HAEMATOLOGICAL MALIGNANCIES (MEAN DIFFERENCE (MD) -0.30, 95% CONFIDENCE INTERVAL (CI) -5.55 TO 4.95; P = 0.91). SIMILARLY, THERE IS NO EVIDENCE OF A DIFFERENCE BETWEEN EITHER GROUP FOR FATIGUE (MD 0.00, 95% CI -0.94 TO 0.94; P = 1.00), ANXIETY (MD 0.30, 95% CI -5.01 TO 5.61; P = 0.91) OR DEPRESSION (MD -0.70, 95% CI -3.21 TO 1.81; P = 0.58).THERE IS VERY LOW QUALITY EVIDENCE THAT YOGA IMPROVES THE OVERALL QUALITY OF SLEEP (MD -2.30, 95% CI -3.78 TO -0.82; P = 0.002). THE YOGA GROUPS' TOTAL SCORE FOR THE PITTSBURGH SLEEP QUALITY INDEX (PSQI) WAS 5.8 (+/- 2.3 SD) AND BETTER THAN THE TOTAL SCORE (8.1 (+/- 2.4 SD)) OF THE CONTROL GROUP. A PSQI TOTAL SCORE OF 0 TO 5 INDICATES GOOD SLEEP WHEREAS PSQI TOTAL SCORE 6 TO 21 POINTS TOWARDS SIGNIFICANT SLEEP DISTURBANCES. THE OCCURRENCE OF AES WAS NOT REPORTED. AUTHORS' CONCLUSIONS: THE CURRENTLY AVAILABLE DATA PROVIDE LITTLE INFORMATION ABOUT THE EFFECTIVENESS OF YOGA INTERVENTIONS FOR PEOPLE SUFFERING FROM HAEMATOLOGICAL MALIGNANCIES. THE FINDING THAT YOGA MAY BE BENEFICIAL FOR THE PATIENTS' QUALITY OF SLEEP IS BASED ON A VERY SMALL BODY OF EVIDENCE. THEREFORE, THE ROLE OF YOGA AS AN ADDITIONAL THERAPY FOR HAEMATOLOGICAL MALIGNANCIES REMAINS UNCLEAR. FURTHER HIGH-QUALITY RANDOMISED CONTROLLED TRIALS WITH LARGER NUMBERS OF PARTICIPANTS ARE NEEDED TO MAKE A DEFINITIVE STATEMENT. 2014 10 2820 58 YOGA TREATMENT FOR CHRONIC NON-SPECIFIC LOW BACK PAIN (2017). WIELAND LS, SKOETZ N, PILKINGTON K, VEMPATI R, DADAMO CR, BERMAN BM. YOGA TREATMENT FOR CHRONIC NON-SPECIFIC LOW BACK PAIN.COCHRANE DATABASE SYST REV2017, ISSUE 1. ART. NO.: CD010671. DOI: 10.1002/14651858.CD010671.PUB2. BACKGROUND: NON-SPECIFIC LOW BACK PAIN IS A COMMON, POTENTIALLY DISABLING CONDITION USUALLY TREATED WITH SELF-CARE AND NON-PRESCRIPTION MEDICATION. FOR CHRONIC LOW BACK PAIN, CURRENT GUIDELINES STATE THAT EXERCISE THERAPY MAY BE BENEFICIAL. YOGA IS A MIND-BODY EXERCISE SOMETIMES USED FOR NON-SPECIFIC LOW BACK PAIN. OBJECTIVES: TO ASSESS THE EFFECTS OF YOGA FOR TREATING CHRONIC NON-SPECIFIC LOW BACK PAIN, COMPARED TO NO SPECIFIC TREATMENT, A MINIMAL INTERVENTION (E.G., EDUCATION), OR ANOTHER ACTIVE TREATMENT, WITH A FOCUS ON PAIN, FUNCTION, AND ADVERSE EVENTS. SEARCH METHODS: WE SEARCHED CENTRAL, MEDLINE, EMBASE, FIVE OTHER DATABASES, AND FOUR TRIALS REGISTERS TO 11 MARCH 2016 WITHOUT RESTRICTION OF LANGUAGE OR PUBLICATION STATUS. WE SCREENED REFERENCE LISTS AND CONTACTED EXPERTS IN THE FIELD TO IDENTIFY ADDITIONAL STUDIES. SELECTION CRITERIA: WE INCLUDED RANDOMIZED CONTROLLED TRIALS OF YOGA TREATMENT IN PEOPLE WITH CHRONIC NON-SPECIFIC LOW BACK PAIN. WE INCLUDED STUDIES COMPARING YOGA TO ANY OTHER INTERVENTION OR TO NO INTERVENTION. WE ALSO INCLUDED STUDIES COMPARING YOGA AS AN ADJUNCT TO OTHER THERAPIES, VERSUS THOSE OTHER THERAPIES ALONE. DATA COLLECTION AND ANALYSIS: TWO AUTHORS INDEPENDENTLY SCREENED AND SELECTED STUDIES, EXTRACTED OUTCOME DATA, AND ASSESSED RISK OF BIAS. WE CONTACTED STUDY AUTHORS TO OBTAIN MISSING OR UNCLEAR INFORMATION. WE EVALUATED THE OVERALL CERTAINTY OF EVIDENCE USING THE GRADE APPROACH. MAIN RESULTS: WE INCLUDED 12 TRIALS (1080 PARTICIPANTS) CARRIED OUT IN THE USA (SEVEN TRIALS), INDIA (THREE TRIALS), AND THE UK (TWO TRIALS). STUDIES WERE UNFUNDED (ONE TRIAL), FUNDED BY A YOGA INSTITUTION (ONE TRIAL), FUNDED BY NON-PROFIT OR GOVERNMENT SOURCES (SEVEN TRIALS), OR DID NOT REPORT ON FUNDING (THREE TRIALS). MOST TRIALS USED IYENGAR, HATHA, OR VINIYOGA FORMS OF YOGA. THE TRIALS COMPARED YOGA TO NO INTERVENTION OR A NON-EXERCISE INTERVENTION SUCH AS EDUCATION (SEVEN TRIALS), AN EXERCISE INTERVENTION (THREE TRIALS), OR BOTH EXERCISE AND NON-EXERCISE INTERVENTIONS (TWO TRIALS). ALL TRIALS WERE AT HIGH RISK OF PERFORMANCE AND DETECTION BIAS BECAUSE PARTICIPANTS AND PROVIDERS WERE NOT BLINDED TO TREATMENT ASSIGNMENT, AND OUTCOMES WERE SELF-ASSESSED. THEREFORE, WE DOWNGRADED ALL OUTCOMES TO "MODERATE" CERTAINTY EVIDENCE BECAUSE OF RISK OF BIAS, AND WHEN THERE WAS ADDITIONAL SERIOUS RISK OF BIAS, UNEXPLAINED HETEROGENEITY BETWEEN STUDIES, OR THE ANALYSES WERE IMPRECISE, WE DOWNGRADED THE CERTAINTY OF THE EVIDENCE FURTHER. FOR YOGA COMPARED TO NON-EXERCISE CONTROLS (9 TRIALS; 810 PARTICIPANTS), THERE WAS LOW-CERTAINTY EVIDENCE THAT YOGA PRODUCED SMALL TO MODERATE IMPROVEMENTS IN BACK-RELATED FUNCTION AT THREE TO FOUR MONTHS [STANDARDIZED MEAN DIFFERENCE (SMD) = -0.40, 95% CI: -0.66 TO -0.14; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MEAN DIFFERENCE (MD) = -2.18, 95% CI: -3.60 TO -0.76], MODERATE-CERTAINTY EVIDENCE FOR SMALL TO MODERATE IMPROVEMENTS AT SIX MONTHS (SMD = -0.44, 95% CI: -0.66 TO -0.22; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD = -2.15, 95% CI: -3.23 TO -1.08), AND LOW-CERTAINTY EVIDENCE FOR SMALL IMPROVEMENTS AT 12 MONTHS (SMD = -0.26, 95% CI: -0.46 TO -0.05; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD = -1.36, 95% CI: -2.41 TO -0.26). ON A 0-100 SCALE THERE WAS VERY LOW- TO MODERATE-CERTAINTY EVIDENCE THAT YOGA WAS SLIGHTLY BETTER FOR PAIN AT THREE TO FOUR MONTHS (MD = -4.55, 95% CI: -7.04 TO -2.06), SIX MONTHS (MD = -7.81, 95% CI: -13.37 TO -2.25), AND 12 MONTHS (MD = -5.40, 95% CI: -14.50 TO -3.70); HOWEVER, WE PRE-DEFINED CLINICALLY SIGNIFICANT CHANGES IN PAIN AS 15 POINTS OR GREATER AND THIS THRESHOLD WAS NOT MET. BASED ON INFORMATION FROM SIX TRIALS, THERE WAS MODERATE-CERTAINTY EVIDENCE THAT THE RISK OF ADVERSE EVENTS, PRIMARILY INCREASED BACK PAIN, WAS HIGHER IN YOGA THAN IN NON-EXERCISE CONTROLS [RISK DIFFERENCE (RD) = 5%, 95% CI: 2-8%]. FOR YOGA COMPARED TO NON-YOGA EXERCISE CONTROLS (4 TRIALS; 394 PARTICIPANTS), THERE WAS VERY-LOW-CERTAINTY EVIDENCE FOR LITTLE OR NO DIFFERENCE IN BACK-RELATED FUNCTION AT THREE MONTHS (SMD = -0.22, 95% CI: -0.65 TO 0.20; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD = -0.99, 95% CI: -2.87 TO 0.90) AND SIX MONTHS (SMD = -0.20, 95% CI: -0.59 TO 0.19; CORRESPONDING TO A CHANGE IN THE ROLAND-MORRIS DISABILITY QUESTIONNAIRE OF MD = -0.90, 95% CI: -2.61 TO 0.81), AND NO INFORMATION ON BACK-RELATED FUNCTION AFTER SIX MONTHS. THERE WAS VERY LOW-CERTAINTY EVIDENCE FOR LOWER PAIN ON A 0-100 SCALE AT SEVEN MONTHS (MD = -20.40, 95% CI: -25.48 TO -15.32), AND NO INFORMATION ON PAIN AT THREE MONTHS OR AFTER SEVEN MONTHS. BASED ON INFORMATION FROM THREE TRIALS, THERE WAS LOW-CERTAINTY EVIDENCE FOR NO DIFFERENCE IN THE RISK OF ADVERSE EVENTS BETWEEN YOGA AND NON-YOGA EXERCISE CONTROLS (RD = 1%, 95% CI: -4% TO 6%). FOR YOGA ADDED TO EXERCISE COMPARED TO EXERCISE ALONE (1 TRIAL; 24 PARTICIPANTS), THERE WAS VERY-LOW-CERTAINTY EVIDENCE FOR LITTLE OR NO DIFFERENCE AT 10 WEEKS IN BACK-RELATED FUNCTION (SMD = -0.60, 95% CI: -1.42 TO 0.22; CORRESPONDING TO A CHANGE IN THE OSWESTRY DISABILITY INDEX OF MD = -17.05, 95% CI: -22.96 TO 11.14) OR PAIN ON A 0-100 SCALE (MD = -3.20, 95% CI: -13.76 TO 7.36). THERE WAS NO INFORMATION ON OUTCOMES AT OTHER TIME POINTS. THERE WAS NO INFORMATION ON ADVERSE EVENTS. STUDIES PROVIDED LIMITED EVIDENCE ON RISK OF CLINICAL IMPROVEMENT, MEASURES OF QUALITY OF LIFE, AND DEPRESSION. THERE WAS NO EVIDENCE ON WORK-RELATED DISABILITY. 2017 11 2518 49 YOGA COMPARED TO NON-EXERCISE OR PHYSICAL THERAPY EXERCISE ON PAIN, DISABILITY, AND QUALITY OF LIFE FOR PATIENTS WITH CHRONIC LOW BACK PAIN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS. BACKGROUND: CHRONIC LOW BACK PAIN (CLBP) IS A COMMON AND OFTEN DISABLING MUSCULOSKELETAL CONDITION. YOGA HAS BEEN PROVEN TO BE AN EFFECTIVE THERAPY FOR CHRONIC LOW BACK PAIN. HOWEVER, THERE ARE STILL CONTROVERSIES ABOUT THE EFFECTS OF YOGA AT DIFFERENT FOLLOW-UP PERIODS AND COMPARED WITH OTHER PHYSICAL THERAPY EXERCISES. OBJECTIVE: TO CRITICALLY COMPARE THE EFFECTS OF YOGA FOR PATIENTS WITH CHRONIC LOW BACK PAIN ON PAIN, DISABILITY, QUALITY OF LIFE WITH NON-EXERCISE (E.G. USUAL CARE, EDUCATION), PHYSICAL THERAPY EXERCISE. METHODS: THIS STUDY WAS REGISTERED IN PROSPERO, AND THE REGISTRATION NUMBER WAS CRD42020159865. RANDOMIZED CONTROLLED TRIALS (RCTS) OF ONLINE DATABASES INCLUDED PUBMED, WEB OF SCIENCE, COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS, EMBASE WHICH EVALUATED EFFECTS OF YOGA FOR PATIENTS WITH CHRONIC LOW BACK PAIN ON PAIN, DISABILITY, AND QUALITY OF LIFE WERE SEARCHED FROM INCEPTION TIME TO NOVEMBER 1, 2019. STUDIES WERE ELIGIBLE IF THEY ASSESSED AT LEAST ONE IMPORTANT OUTCOME, NAMELY PAIN, BACK-SPECIFIC DISABILITY, QUALITY OF LIFE. THE COCHRANE RISK OF BIAS TOOL WAS USED TO ASSESS THE METHODOLOGICAL QUALITY OF INCLUDED RANDOMIZED CONTROLLED TRIALS. THE CONTINUOUS OUTCOMES WERE ANALYZED BY CALCULATING THE MEAN DIFFERENCE (MD) OR STANDARDIZED MEAN DIFFERENCE (SMD) WITH 95% CONFIDENCE INTERVALS (CI) ACCORDING TO WHETHER COMBINING OUTCOMES MEASURED ON DIFFERENT SCALES OR NOT. RESULTS: A TOTAL OF 18 RANDOMIZED CONTROLLED TRIALS WERE INCLUDED IN THIS META-ANALYSIS. YOGA COULD SIGNIFICANTLY REDUCE PAIN AT 4 TO 8 WEEKS (MD = -0.83, 95% CI = -1.19 TO -0.48, P<0.00001, I2 = 0%), 3 MONTHS (MD = -0.43, 95% CI = -0.64 TO -0.23, P<0.0001, I2 = 0%), 6 TO 7 MONTHS (MD = -0.56, 95% CI = -1.02 TO -0.11, P = 0.02, I2 = 50%), AND WAS NOT SIGNIFICANT IN 12 MONTHS (MD = -0.52, 95% CI = -1.64 TO 0.59, P = 0.36, I2 = 87%) COMPARED WITH NON-EXERCISE. YOGA WAS BETTER THAN NON-EXERCISE ON DISABILITY AT 4 TO 8 WEEKS (SMD = -0.30, 95% CI = -0.51 TO -0.10, P = 0.003, I2 = 0%), 3 MONTHS (SMD = -0.31, 95% CI = -0.45 TO -0.18, P<0.00001, I2 = 30%), 6 MONTHS (SMD = -0.38, 95% CI = -0.53 TO -0.23, P<0.00001, I2 = 0%), 12 MONTHS (SMD = -0.33, 95% CI = -0.54 TO -0.12, P = 0.002, I2 = 9%). THERE WAS NO SIGNIFICANT DIFFERENCE ON PAIN, DISABILITY COMPARED WITH PHYSICAL THERAPY EXERCISE GROUP. FURTHERMORE, IT SUGGESTED THAT THERE WAS A NON-SIGNIFICANT DIFFERENCE ON PHYSICAL AND MENTAL QUALITY OF LIFE BETWEEN YOGA AND ANY OTHER INTERVENTIONS. CONCLUSION: THIS META-ANALYSIS PROVIDED EVIDENCE FROM VERY LOW TO MODERATE INVESTIGATING THE EFFECTIVENESS OF YOGA FOR CHRONIC LOW BACK PAIN PATIENTS AT DIFFERENT TIME POINTS. YOGA MIGHT DECREASE PAIN FROM SHORT TERM TO INTERMEDIATE TERM AND IMPROVE FUNCTIONAL DISABILITY STATUS FROM SHORT TERM TO LONG TERM COMPARED WITH NON-EXERCISE (E.G. USUAL CARE, EDUCATION). YOGA HAD THE SAME EFFECT ON PAIN AND DISABILITY AS ANY OTHER EXERCISE OR PHYSICAL THERAPY. YOGA MIGHT NOT IMPROVE THE PHYSICAL AND MENTAL QUALITY OF LIFE BASED ON THE RESULT OF A MERGING. 2020 12 2829 53 YOGA VERSUS STANDARD CARE FOR SCHIZOPHRENIA. BACKGROUND: YOGA IS AN ANCIENT SPIRITUAL PRACTICE THAT ORIGINATED IN INDIA AND IS CURRENTLY ACCEPTED IN THE WESTERN WORLD AS A FORM OF RELAXATION AND EXERCISE. IT HAS BEEN OF INTEREST FOR PEOPLE WITH SCHIZOPHRENIA TO DETERMINE ITS EFFICACY AS AN ADJUNCT TO STANDARD-CARE TREATMENT. OBJECTIVES: TO EXAMINE THE EFFECTS OF YOGA VERSUS STANDARD CARE FOR PEOPLE WITH SCHIZOPHRENIA. SEARCH METHODS: WE SEARCHED THE COCHRANE SCHIZOPHRENIA GROUP TRIALS REGISTER (NOVEMBER 2012 AND JANUARY 29, 2015), WHICH IS BASED ON REGULAR SEARCHES OF MEDLINE, PUBMED, EMBASE, CINAHL, BIOSIS, AMED, PSYCINFO, AND REGISTRIES OF CLINICAL TRIALS. WE SEARCHED THE REFERENCES OF ALL INCLUDED STUDIES. THERE WERE NO LANGUAGE, DATE, DOCUMENT TYPE, OR PUBLICATION STATUS LIMITATIONS FOR INCLUSION OF RECORDS IN THE REGISTER. SELECTION CRITERIA: ALL RANDOMISED CONTROLLED TRIALS (RCTS) INCLUDING PEOPLE WITH SCHIZOPHRENIA COMPARING YOGA TO STANDARD-CARE CONTROL. DATA COLLECTION AND ANALYSIS: THE REVIEW TEAM INDEPENDENTLY SELECTED STUDIES, QUALITY RATED THESE, AND EXTRACTED DATA. FOR BINARY OUTCOMES, WE CALCULATED RISK RATIO (RR) AND ITS 95% CONFIDENCE INTERVAL (CI), ON AN INTENTION-TO-TREAT BASIS. FOR CONTINUOUS DATA, WE ESTIMATED THE MEAN DIFFERENCE (MD) BETWEEN GROUPS AND ITS 95% CI. WE EMPLOYED MIXED-EFFECT AND FIXED-EFFECT MODELS FOR ANALYSES. WE EXAMINED DATA FOR HETEROGENEITY (I(2) TECHNIQUE), ASSESSED RISK OF BIAS FOR INCLUDED STUDIES, AND CREATED 'SUMMARY OF FINDINGS' TABLES USING GRADE (GRADING OF RECOMMENDATIONS ASSESSMENT, DEVELOPMENT AND EVALUATION). MAIN RESULTS: WE INCLUDED EIGHT STUDIES IN THE REVIEW. ALL OUTCOMES WERE SHORT TERM (LESS THAN SIX MONTHS). THERE WERE CLEAR DIFFERENCES IN A NUMBER OF OUTCOMES IN FAVOUR OF THE YOGA GROUP, ALTHOUGH THESE WERE BASED ON ONE STUDY EACH, WITH THE EXCEPTION OF LEAVING THE STUDY EARLY. THESE INCLUDED MENTAL STATE (IMPROVEMENT IN POSITIVE AND NEGATIVE SYNDROME SCALE, 1 RCT, N = 83, RR 0.70 CI 0.55 TO 0.88, MEDIUM-QUALITY EVIDENCE), SOCIAL FUNCTIONING (IMPROVEMENT IN SOCIAL OCCUPATIONAL FUNCTIONING SCALE, 1 RCT, N = 83, RR 0.88 CI 0.77 TO 1, MEDIUM-QUALITY EVIDENCE), QUALITY OF LIFE (AVERAGE CHANGE 36-ITEM SHORT FORM SURVEY (SF-36) QUALITY-OF-LIFE SUBSCALE, 1 RCT, N = 60, MD 15.50, 95% CI 4.27 TO 26.73, LOW-QUALITY EVIDENCE), AND LEAVING THE STUDY EARLY (8 RCTS, N = 457, RR 0.91 CI 0.6 TO 1.37, MEDIUM-QUALITY EVIDENCE). FOR THE OUTCOME OF PHYSICAL HEALTH, THERE WAS NOT A CLEAR DIFFERENCE BETWEEN GROUPS (AVERAGE CHANGE SF-36 PHYSICAL-HEALTH SUBSCALE, 1 RCT, N = 60, MD 6.60, 95% CI -2.44 TO 15.64, LOW-QUALITY EVIDENCE). ONLY ONE STUDY REPORTED ADVERSE EFFECTS, FINDING NO INCIDENCE OF ADVERSE EVENTS IN EITHER TREATMENT GROUP. THIS REVIEW WAS SUBJECT TO A CONSIDERABLE NUMBER OF MISSING OUTCOMES, WHICH INCLUDED GLOBAL STATE, CHANGE IN COGNITION, COSTS OF CARE, EFFECT ON STANDARD CARE, SERVICE INTERVENTION, DISABILITY, AND ACTIVITIES OF DAILY LIVING. AUTHORS' CONCLUSIONS: EVEN THOUGH WE FOUND SOME POSITIVE EVIDENCE IN FAVOUR OF YOGA OVER STANDARD-CARE CONTROL, THIS SHOULD BE INTERPRETED CAUTIOUSLY IN VIEW OF OUTCOMES LARGELY BASED EACH ON ONE STUDY WITH LIMITED SAMPLE SIZES AND SHORT-TERM FOLLOW-UP. OVERALL, MANY OUTCOMES WERE NOT REPORTED AND EVIDENCE PRESENTED IN THIS REVIEW IS OF LOW TO MODERATE QUALITY - -TOO WEAK TO INDICATE THAT YOGA IS SUPERIOR TO STANDARD-CARE CONTROL FOR THE MANAGEMENT OF SCHIZOPHRENIA. 2015 13 2614 39 YOGA FOR SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS. BACKGROUND: THE AIM OF THIS REVIEW WAS TO SYSTEMATICALLY REVIEW AND META-ANALYZE THE EFFECTS OF YOGA ON SYMPTOMS OF SCHIZOPHRENIA, QUALITY OF LIFE, FUNCTION, AND HOSPITALIZATION IN PATIENTS WITH SCHIZOPHRENIA. METHODS: MEDLINE/PUBMED, SCOPUS, THE COCHRANE LIBRARY, PSYCINFO, AND INDMED WERE SCREENED THROUGH AUGUST 2012. RANDOMIZED CONTROLLED TRIALS (RCTS) COMPARING YOGA TO USUAL CARE OR NON-PHARMACOLOGICAL INTERVENTIONS WERE ANALYZED WHEN THEY ASSESSED SYMPTOMS OR QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA. COGNITIVE FUNCTION, SOCIAL FUNCTION, HOSPITALIZATION, AND SAFETY WERE DEFINED AS SECONDARY OUTCOMES. RISK OF BIAS WAS ASSESSED USING THE RISK OF BIAS TOOL RECOMMENDED BY THE COCHRANE BACK REVIEW GROUP. STANDARDIZED MEAN DIFFERENCES (SMD) AND 95% CONFIDENCE INTERVALS (CI) WERE CALCULATED. RESULTS: FIVE RCTS WITH A TOTAL OF 337 PATIENTS WERE INCLUDED; 2 RCTS HAD LOW RISK OF BIAS. TWO RCTS COMPARED YOGA TO USUAL CARE; 1 RCT COMPARED YOGA TO EXERCISE; AND 2 3-ARM RCTS COMPARED YOGA TO USUAL CARE AND EXERCISE. NO EVIDENCE WAS FOUND FOR SHORT-TERM EFFECTS OF YOGA COMPARED TO USUAL CARE ON POSITIVE SYMPTOMS (SMD = -0.58; 95% CI -1.52 TO 0.37; P = 0.23), OR NEGATIVE SYMPTOMS (SMD = -0.59; 95% CI -1.87 TO 0.69; P = 0.36). MODERATE EVIDENCE WAS FOUND FOR SHORT-TERM EFFECTS ON QUALITY OF LIFE COMPARED TO USUAL CARE (SMD = 2.28; 95% CI 0.42 TO 4.14; P = 0.02). THESE EFFECTS WERE ONLY PRESENT IN STUDIES WITH HIGH RISK OF BIAS. NO EVIDENCE WAS FOUND FOR SHORT-TERM EFFECTS ON SOCIAL FUNCTION (SMD = 1.20; 95% CI -0.78 TO 3.18; P = 0.23). COMPARING YOGA TO EXERCISE, NO EVIDENCE WAS FOUND FOR SHORT-TERM EFFECTS ON POSITIVE SYMPTOMS (SMD = -0.35; 95% CI -0.75 TO 0.05; P = 0.09), NEGATIVE SYMPTOMS (SMD = -0.28; 95% CI -1.42 TO 0.86; P = 0.63), QUALITY OF LIFE (SMD = 0.17; 95% CI -0.27 TO 0.61; P = 0.45), OR SOCIAL FUNCTION (SMD = 0.20; 95% CI -0.27 TO 0.67; P = 0.41). ONLY 1 RCT REPORTED ADVERSE EVENTS. CONCLUSIONS: THIS SYSTEMATIC REVIEW FOUND ONLY MODERATE EVIDENCE FOR SHORT-TERM EFFECTS OF YOGA ON QUALITY OF LIFE. AS THESE EFFECTS WERE NOT CLEARLY DISTINGUISHABLE FROM BIAS AND SAFETY OF THE INTERVENTION WAS UNCLEAR, NO RECOMMENDATION CAN BE MADE REGARDING YOGA AS A ROUTINE INTERVENTION FOR SCHIZOPHRENIA PATIENTS. 2013 14 2633 38 YOGA FOR TREATING HEADACHES: A SYSTEMATIC REVIEW AND META-ANALYSIS. BACKGROUND: HEADACHE DISORDERS ARE CURRENTLY THE SIXTH LEADING CAUSE OF DISABILITY ACROSS THE GLOBE AND THEREFORE CARRY A SIGNIFICANT DISEASE BURDEN. THIS SYSTEMATIC REVIEW AND META-ANALYSIS AIMS TO INVESTIGATE THE EFFECTS OF YOGA ON HEADACHE DISORDERS. METHODS: MEDLINE/PUBMED, SCOPUS, THE COCHRANE LIBRARY, AND PSYCINFO WERE SCREENED THROUGH MAY 2019. RANDOMIZED CONTROLLED TRIALS (RCTS) WERE INCLUDED WHEN THEY ASSESSED THE EFFECTS OF YOGA IN PATIENTS WITH A DIAGNOSIS OF CHRONIC OR EPISODIC HEADACHE (TENSION-TYPE HEADACHE AND/OR MIGRAINE). USUAL CARE (NO SPECIFIC TREATMENT) OR ANY ACTIVE TREATMENTS WERE ACCEPTABLE AS CONTROL INTERVENTIONS. PRIMARY OUTCOME MEASURES WERE HEADACHE FREQUENCY, HEADACHE DURATION, AND PAIN INTENSITY. FOR EACH OUTCOME, STANDARDIZED MEAN DIFFERENCES (SMD) AND 95% CONFIDENCE INTERVALS (CI) WERE CALCULATED. RESULTS: META-ANALYSIS REVEALED A STATISTICALLY SIGNIFICANT OVERALL EFFECT IN FAVOR OF YOGA FOR HEADACHE FREQUENCY (5 RCTS; STANDARDIZED MEAN DIFFERENCE (SMD) = - 1.97; 95% CONFIDENCE INTERVAL (CI) - 2.75 TO - 1.20; I(2) = 63.0%, TAU(2) = 0.25, P = 0.03), HEADACHE DURATION (4 RCTS; SMD = - 1.45; 95% CI - 2.54 TO - 0.37; I(2) = 69.0%, TAU(2) = 0.33, P = 0.02), AND PAIN INTENSITY (5 RCTS; SMD = - 3.43; 95% CI - 6.08 TO - 0.70, I(2) = 95.0%, TAU(2) = 4.25, P < 0.01). THE SIGNIFICANT OVERALL EFFECT WAS MAINLY DUE TO PATIENTS WITH TENSION-TYPE HEADACHES. FOR PATIENTS WITH MIGRAINE, NO STATISTICALLY SIGNIFICANT EFFECT WAS OBSERVED. DISCUSSION: DESPITE DISCUSSED LIMITATIONS, THIS REVIEW FOUND PRELIMINARY EVIDENCE OF SHORT-TERM EFFICACY OF YOGA IN IMPROVING HEADACHE FREQUENCY, HEADACHE DURATION, AND PAIN INTENSITY IN PATIENTS SUFFERING FROM TENSION-TYPE HEADACHES. FURTHER STUDIES ARE URGENTLY NEEDED TO DRAW DEEPER CONCLUSIONS FROM THE AVAILABLE RESULTS. 2020 15 602 35 DEVELOPMENT AND VALIDATION OF A YOGA MODULE FOR PARKINSON DISEASE. BACKGROUND PARKINSON'S DISEASE (PD), A PROGRESSIVE NEURODEGENERATIVE DISEASE, AFFECTS MOTOR AND NONMOTOR FUNCTIONS, LEADING TO SEVERE DEBILITY AND POOR QUALITY OF LIFE. STUDIES HAVE REPORTED THE BENEFICIAL ROLE OF YOGA IN ALLEVIATING THE SYMPTOMS OF PD; HOWEVER, A VALIDATED YOGA MODULE FOR PD IS UNAVAILABLE. THIS STUDY DEVELOPED AND VALIDATED AN INTEGRATED YOGA MODULE(IYM) FOR PD. METHODS THE IYM WAS PREPARED AFTER A THOROUGH REVIEW OF CLASSICAL YOGA TEXTS AND PREVIOUS FINDINGS. TWENTY EXPERIENCED YOGA EXPERTS, WHO FULFILLED THE INCLUSION CRITERIA, WERE SELECTED VALIDATING THE CONTENT OF THE IYM. A TOTAL OF 28 PRACTICES WERE INCLUDED IN THE IYM, AND EACH PRACTICE WAS DISCUSSED AND RATED AS (I) NOT ESSENTIAL, (II) USEFUL BUT NOT ESSENTIAL, AND (III) ESSENTIAL; THE CONTENT VALIDITY RATIO (CVR) WAS CALCULATED USING LAWSHE'S FORMULA. RESULTS DATA ANALYSIS REVEALED THAT OF THE 28 IYM PRACTICES, 21 EXHIBITED SIGNIFICANT CONTENT VALIDITY (CUT-OFF VALUE: 0.42, AS CALCULATED BY APPLYING LAWSHE'S FORMULA FOR THE CVR). CONCLUSIONS THE IYM IS VALID FOR PD, WITH GOOD CONTENT VALIDITY. HOWEVER, FUTURE STUDIES MUST DETERMINE THE FEASIBILITY AND EFFICACY OF THE DEVELOPED MODULE. 2017 16 1139 25 EFFICACY OF YOGA TRAINING IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS. OBJECTIVES: TO EVALUATE THE IMPACT OF YOGA TRAINING IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). METHOD: A LITERATURE SEARCH WAS PERFORMED IN PUBMED, COCHRANE LIBRARY, EMBASE, CINAHL, AND WEB OF SCIENCE FOR RELEVANT STUDIES PUBLISHED BEFORE JUNE 2017. QUALITY ASSESSMENT, SENSITIVITY ANALYSIS AND HETEROGENEITY WERE PERFORMED. STATA12.0 SOFTWARE WAS USED FOR STATISTICAL ANALYSIS. RESULTS: TEN STUDIES WERE ELIGIBLE FOR THIS ANALYSIS. THERE WERE SIGNIFICANTLY GREATER IMPROVEMENTS IN 6MWD (P = 0.000), BORG SCALE SCORES (P = 0.018), FEV1 VALUE (P = 0. 013), PACO2 (P = 0.037), SGRQ SCORES (P = 0. 000) AND CAT SCORES (P = 0.009) IN YOGA TRAINING PATIENTS. NO STATISTICALLY SIGNIFICANT DIFFERENCE WAS OBSERVED IN THE FEV1/FVC (P = 0.75), FEV1 PREDICTED VALUE (P = 0.057) AND FVC (P = 0.05). CONCLUSIONS: THIS META-ANALYSIS INDICATES THAT YOGA TRAINING CAN BE AN ACCEPTABLE AND APPROPRIATED ADJUNCTIVE REHABILITATION PROGRAM FOR COPD PATIENTS. 2018 17 2583 36 YOGA FOR HEART RATE VARIABILITY: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS. THE OBJECTIVE OF THIS SYSTEMATIC REVIEW IS TO SUMMARIZE AND CRITICALLY ASSESS THE EFFECTS OF YOGA ON HEART RATE VARIABILITY (HRV). NINE DATABASES WERE SEARCHED FROM THEIR INCEPTIONS TO JUNE 2014. WE INCLUDED RANDOMIZED CLINICAL TRIALS (RCTS) COMPARING YOGA AGAINST ANY TYPE OF CONTROL INTERVENTION IN HEALTHY INDIVIDUALS OR PATIENTS WITH ANY MEDICAL CONDITION. RISK OF BIAS WAS ASSESSED USING THE COCHRANE CRITERIA. TWO REVIEWERS PERFORMED THE SELECTION OF STUDIES, DATA EXTRACTION, AND QUALITY ASSESSMENTS INDEPENDENT OF ONE ANOTHER. FOURTEEN TRIALS MET THE INCLUSION CRITERIA. ONLY TWO OF THEM WERE OF ACCEPTABLE METHODOLOGICAL QUALITY. TEN RCTS REPORTED FAVOURABLE EFFECTS OF YOGA ON VARIOUS DOMAINS OF HRV, WHEREAS NINE OF THEM FAILED TO DO SO. ONE RCT DID NOT REPORT BETWEEN-GROUP COMPARISONS. THE META-ANALYSIS (MA) OF TWO TRIALS DID NOT SHOW FAVOURABLE EFFECTS OF YOGA COMPARED TO USUAL CARE ON E:I RATIO (N = 61, SMDS = 0.63; 95% CIS [-0.72 TO 1.99], P = 0.36; HETEROGENEITY: R(2) = 0.79, CHI(2) = 5.48, DF = 1, (P = 0.02); I(2) = 82%). THE MA ALSO FAILED TO SHOW STATISTICALLY SIGNIFICANT DIFFERENCES BETWEEN THE GROUPS REGARDING THE 30:15 RATIO (N = 61, SMDS = 0.20; 95% CIS [-0.43 TO 0.84], P = 0.53; HETEROGENEITY: R(2) = 0.07, CHI(2) = 1.45, DF = 1, (P = 0.23); I(2) = 31%). THE DATA FROM THE REMAINING RCTS WERE TOO HETEROGENEOUS FOR POOLING. THESE RESULTS PROVIDE NO CONVINCING EVIDENCE FOR THE EFFECTIVENESS OF YOGA IN MODULATING HRV IN PATIENTS OR HEALTHY SUBJECTS. FUTURE INVESTIGATIONS IN THIS AREA SHOULD OVERCOME THE MULTIPLE METHODOLOGICAL WEAKNESSES OF THE PREVIOUS RESEARCH. 2015 18 1374 42 IMPACT OF AN INTEGRATED YOGA THERAPY PROTOCOL ON INSULIN RESISTANCE AND GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. OBJECTIVE: DIABETES MELLITUS (DM), CHARACTERIZED BY CHRONIC HYPERGLYCEMIA, IS ATTRIBUTED TO RELATIVE INSULIN DEFICIENCY OR RESISTANCE, OR BOTH. STUDIES HAVE SHOWN THAT YOGA CAN MODULATE PARAMETERS OF INSULIN RESISTANCE. THE PRESENT STUDY EXPLORED THE POSSIBLE BENEFICIAL EFFECTS OF INTEGRATED YOGA THERAPY WITH REFERENCE TO GLYCEMIC CONTROL AND INSULIN RESISTANCE (IR) IN INDIVIDUALS WITH DIABETES MAINTAINED ON STANDARD ORAL MEDICAL CARE WITH YOGA THERAPY, COMPARED TO THOSE ON STANDARD ORAL MEDICAL CARE ALONE. METHODS: IN THIS STUDY, THE SUBJECTS ON YOGA INTERVENTION COMPRISED 35 TYPE 2 DIABETICS, AND AN EQUAL NUMBER OF VOLUNTEERS CONSTITUTED THE CONTROL GROUP. SUBJECTS RANGED IN AGE FROM 30 TO 70 YEARS, WITH HEMOGLOBIN A1C (HBA1C) TEST MORE THAN 7%, AND WERE MAINTAINED ON DIABETIC DIET AND ORAL HYPOGLYCEMIC AGENTS. BLOOD SAMPLES WERE DRAWN PRIOR TO AND AFTER 120 DAYS OF INTEGRATED YOGA THERAPY INTERVENTION. FASTING BLOOD GLUCOSE (FBG), POST-PRANDIAL BLOOD GLUCOSE (PPBG), HBA1C, INSULIN, AND LIPID PROFILE WERE ASSESSED IN BOTH THE INTERVENTION AND CONTROL GROUPS. RESULTS: THE INTERVENTION GROUP REVEALED SIGNIFICANT IMPROVEMENTS IN BODY MASS INDEX (BMI) (0.7 KG/M(2) MEDIAN DECREASE; P=0.001), FBG (20 MG/DL MEDIAN DECREASE; P<0.001), PPBG (33 MG/DL MEDIAN DECREASE; P<0.001), HBA1C (0.4% MEDIAN DECREASE; P<0.001), HOMEOSTATIC MODEL ASSESSMENT FOR INSULIN RESISTANCE (HOMA-IR) (1.2 MEDIAN DECREASE; P<0.001), CHOLESTEROL (13 MG/DL MEDIAN DECREASE, P=0.006), TRIACYLGLYCEROL (22 MG/DL MEDIAN DECREASE; P=0.027), LOW-DENSITY LIPOPROTEIN (6 MG/DL MEDIAN DECREASE; P=0.004), AND VERY-LOW-DENSITY LIPOPROTEIN LEVELS (4 MG/DL MEDIAN DECREASE; P=0.032). INCREASES IN HIGH-DENSITY LIPOPROTEIN AFTER 120 DAYS WERE NOT SIGNIFICANT (6 MG/DL MEDIAN INCREASE; P=0.15). HOWEVER, WHEN COMPARED TO CHANGES OBSERVED IN PATIENTS IN THE CONTROL GROUP, ALL THESE IMPROVEMENTS PROVED TO BE SIGNIFICANT. CONCLUSION: ADMINISTRATION OF INTEGRATED YOGA THERAPY TO INDIVIDUALS WITH DIABETES LEADS TO A SIGNIFICANT IMPROVEMENT IN GLYCEMIC CONTROL, INSULIN RESISTANCE, AND KEY BIOCHEMICAL PARAMETERS. 2022 19 2587 53 YOGA FOR IMPROVING HEALTH-RELATED QUALITY OF LIFE, MENTAL HEALTH AND CANCER-RELATED SYMPTOMS IN WOMEN DIAGNOSED WITH BREAST CANCER. BACKGROUND: BREAST CANCER IS THE CANCER MOST FREQUENTLY DIAGNOSED IN WOMEN WORLDWIDE. EVEN THOUGH SURVIVAL RATES ARE CONTINUALLY INCREASING, BREAST CANCER IS OFTEN ASSOCIATED WITH LONG-TERM PSYCHOLOGICAL DISTRESS, CHRONIC PAIN, FATIGUE AND IMPAIRED QUALITY OF LIFE. YOGA COMPRISES ADVICE FOR AN ETHICAL LIFESTYLE, SPIRITUAL PRACTICE, PHYSICAL ACTIVITY, BREATHING EXERCISES AND MEDITATION. IT IS A COMPLEMENTARY THERAPY THAT IS COMMONLY RECOMMENDED FOR BREAST CANCER-RELATED IMPAIRMENTS AND HAS BEEN SHOWN TO IMPROVE PHYSICAL AND MENTAL HEALTH IN PEOPLE WITH DIFFERENT CANCER TYPES. OBJECTIVES: TO ASSESS EFFECTS OF YOGA ON HEALTH-RELATED QUALITY OF LIFE, MENTAL HEALTH AND CANCER-RELATED SYMPTOMS AMONG WOMEN WITH A DIAGNOSIS OF BREAST CANCER WHO ARE RECEIVING ACTIVE TREATMENT OR HAVE COMPLETED TREATMENT. SEARCH METHODS: WE SEARCHED THE COCHRANE BREAST CANCER SPECIALISED REGISTER, MEDLINE (VIA PUBMED), EMBASE, THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS (CENTRAL; 2016, ISSUE 1), INDEXING OF INDIAN MEDICAL JOURNALS (INDMED), THE WORLD HEALTH ORGANIZATION (WHO) INTERNATIONAL CLINICAL TRIALS REGISTRY PLATFORM (ICTRP) SEARCH PORTAL AND CLINICALTRIALS.GOV ON 29 JANUARY 2016. WE ALSO SEARCHED REFERENCE LISTS OF IDENTIFIED RELEVANT TRIALS OR REVIEWS, AS WELL AS CONFERENCE PROCEEDINGS OF THE INTERNATIONAL CONGRESS ON COMPLEMENTARY MEDICINE RESEARCH (ICCMR), THE EUROPEAN CONGRESS FOR INTEGRATIVE MEDICINE (ECIM) AND THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO). WE APPLIED NO LANGUAGE RESTRICTIONS. SELECTION CRITERIA: RANDOMISED CONTROLLED TRIALS WERE ELIGIBLE WHEN THEY (1) COMPARED YOGA INTERVENTIONS VERSUS NO THERAPY OR VERSUS ANY OTHER ACTIVE THERAPY IN WOMEN WITH A DIAGNOSIS OF NON-METASTATIC OR METASTATIC BREAST CANCER, AND (2) ASSESSED AT LEAST ONE OF THE PRIMARY OUTCOMES ON PATIENT-REPORTED INSTRUMENTS, INCLUDING HEALTH-RELATED QUALITY OF LIFE, DEPRESSION, ANXIETY, FATIGUE OR SLEEP DISTURBANCES. DATA COLLECTION AND ANALYSIS: TWO REVIEW AUTHORS INDEPENDENTLY COLLECTED DATA ON METHODS AND RESULTS. WE EXPRESSED OUTCOMES AS STANDARDISED MEAN DIFFERENCES (SMDS) WITH 95% CONFIDENCE INTERVALS (CIS) AND CONDUCTED RANDOM-EFFECTS MODEL META-ANALYSES. WE ASSESSED POTENTIAL RISK OF PUBLICATION BIAS THROUGH VISUAL ANALYSIS OF FUNNEL PLOT SYMMETRY AND HETEROGENEITY BETWEEN STUDIES BY USING THE CHI(2) TEST AND THE I(2) STATISTIC. WE CONDUCTED SUBGROUP ANALYSES FOR CURRENT TREATMENT STATUS, TIME SINCE DIAGNOSIS, STAGE OF CANCER AND TYPE OF YOGA INTERVENTION. MAIN RESULTS: WE INCLUDED 24 STUDIES WITH A TOTAL OF 2166 PARTICIPANTS, 23 OF WHICH PROVIDED DATA FOR META-ANALYSIS. THIRTEEN STUDIES HAD LOW RISK OF SELECTION BIAS, FIVE STUDIES REPORTED ADEQUATE BLINDING OF OUTCOME ASSESSMENT AND 15 STUDIES HAD LOW RISK OF ATTRITION BIAS.SEVENTEEN STUDIES THAT COMPARED YOGA VERSUS NO THERAPY PROVIDED MODERATE-QUALITY EVIDENCE SHOWING THAT YOGA IMPROVED HEALTH-RELATED QUALITY OF LIFE (POOLED SMD 0.22, 95% CI 0.04 TO 0.40; 10 STUDIES, 675 PARTICIPANTS), REDUCED FATIGUE (POOLED SMD -0.48, 95% CI -0.75 TO -0.20; 11 STUDIES, 883 PARTICIPANTS) AND REDUCED SLEEP DISTURBANCES IN THE SHORT TERM (POOLED SMD -0.25, 95% CI -0.40 TO -0.09; SIX STUDIES, 657 PARTICIPANTS). THE FUNNEL PLOT FOR HEALTH-RELATED QUALITY OF LIFE WAS ASYMMETRICAL, FAVOURING NO THERAPY, AND THE FUNNEL PLOT FOR FATIGUE WAS ROUGHLY SYMMETRICAL. THIS HINTS AT OVERALL LOW RISK OF PUBLICATION BIAS. YOGA DID NOT APPEAR TO REDUCE DEPRESSION (POOLED SMD -0.13, 95% CI -0.31 TO 0.05; SEVEN STUDIES, 496 PARTICIPANTS; LOW-QUALITY EVIDENCE) OR ANXIETY (POOLED SMD -0.53, 95% CI -1.10 TO 0.04; SIX STUDIES, 346 PARTICIPANTS; VERY LOW-QUALITY EVIDENCE) IN THE SHORT TERM AND HAD NO MEDIUM-TERM EFFECTS ON HEALTH-RELATED QUALITY OF LIFE (POOLED SMD 0.10, 95% CI -0.23 TO 0.42; TWO STUDIES, 146 PARTICIPANTS; LOW-QUALITY EVIDENCE) OR FATIGUE (POOLED SMD -0.04, 95% CI -0.36 TO 0.29; TWO STUDIES, 146 PARTICIPANTS; LOW-QUALITY EVIDENCE). INVESTIGATORS REPORTED NO SERIOUS ADVERSE EVENTS.FOUR STUDIES THAT COMPARED YOGA VERSUS PSYCHOSOCIAL/EDUCATIONAL INTERVENTIONS PROVIDED MODERATE-QUALITY EVIDENCE INDICATING THAT YOGA CAN REDUCE DEPRESSION (POOLED SMD -2.29, 95% CI -3.97 TO -0.61; FOUR STUDIES, 226 PARTICIPANTS), ANXIETY (POOLED SMD -2.21, 95% CI -3.90 TO -0.52; THREE STUDIES, 195 PARTICIPANTS) AND FATIGUE (POOLED SMD -0.90, 95% CI -1.31 TO -0.50; TWO STUDIES, 106 PARTICIPANTS) IN THE SHORT TERM. VERY LOW-QUALITY EVIDENCE SHOWED NO SHORT-TERM EFFECTS ON HEALTH-RELATED QUALITY OF LIFE (POOLED SMD 0.81, 95% CI -0.50 TO 2.12; TWO STUDIES, 153 PARTICIPANTS) OR SLEEP DISTURBANCES (POOLED SMD -0.21, 95% CI -0.76 TO 0.34; TWO STUDIES, 119 PARTICIPANTS). NO TRIAL ADEQUATELY REPORTED SAFETY-RELATED DATA.THREE STUDIES THAT COMPARED YOGA VERSUS EXERCISE PRESENTED VERY LOW-QUALITY EVIDENCE SHOWING NO SHORT-TERM EFFECTS ON HEALTH-RELATED QUALITY OF LIFE (POOLED SMD -0.04, 95% CI -0.30 TO 0.23; THREE STUDIES, 233 PARTICIPANTS) OR FATIGUE (POOLED SMD -0.21, 95% CI -0.66 TO 0.25; THREE STUDIES, 233 PARTICIPANTS); NO TRIAL PROVIDED SAFETY-RELATED DATA. AUTHORS' CONCLUSIONS: MODERATE-QUALITY EVIDENCE SUPPORTS THE RECOMMENDATION OF YOGA AS A SUPPORTIVE INTERVENTION FOR IMPROVING HEALTH-RELATED QUALITY OF LIFE AND REDUCING FATIGUE AND SLEEP DISTURBANCES WHEN COMPARED WITH NO THERAPY, AS WELL AS FOR REDUCING DEPRESSION, ANXIETY AND FATIGUE, WHEN COMPARED WITH PSYCHOSOCIAL/EDUCATIONAL INTERVENTIONS. VERY LOW-QUALITY EVIDENCE SUGGESTS THAT YOGA MIGHT BE AS EFFECTIVE AS OTHER EXERCISE INTERVENTIONS AND MIGHT BE USED AS AN ALTERNATIVE TO OTHER EXERCISE PROGRAMMES. 2017 20 2629 48 YOGA FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE. BACKGROUND: A SEDENTARY LIFESTYLE AND STRESS ARE MAJOR RISK FACTORS FOR CARDIOVASCULAR DISEASE (CVD). SINCE YOGA INVOLVES EXERCISE AND IS THOUGHT TO HELP IN STRESS REDUCTION IT MAY BE AN EFFECTIVE STRATEGY IN THE PRIMARY PREVENTION OF CVD. OBJECTIVES: TO DETERMINE THE EFFECT OF ANY TYPE OF YOGA ON THE PRIMARY PREVENTION OF CVD. SEARCH METHODS: WE SEARCHED THE FOLLOWING ELECTRONIC DATABASES: THE COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS (CENTRAL) (2013, ISSUE 11) IN THE COCHRANE LIBRARY; MEDLINE (OVID) (1946 TO NOVEMBER WEEK 3 2013); EMBASE CLASSIC + EMBASE (OVID) (1947 TO 2013 WEEK 48); WEB OF SCIENCE (THOMSON REUTERS) (1970 TO 4 DECEMBER 2013); DATABASE OF ABSTRACTS OF REVIEWS OF EFFECTS (DARE), HEALTH TECHNOLOGY ASSESSMENT DATABASE AND HEALTH ECONOMICS EVALUATIONS DATABASE (ISSUE 4 OF 4, 2013) IN THE COCHRANE LIBRARY. WE ALSO SEARCHED A NUMBER OF ASIAN DATABASES AND THE ALLIED AND COMPLEMENTARY MEDICINE DATABASE (AMED) (INCEPTION TO DECEMBER 2012). WE SEARCHED TRIAL REGISTERS AND REFERENCE LISTS OF REVIEWS AND ARTICLES, AND APPROACHED EXPERTS IN THE FIELD. WE APPLIED NO LANGUAGE RESTRICTIONS. SELECTION CRITERIA: RANDOMISED CONTROLLED TRIALS LASTING AT LEAST THREE MONTHS INVOLVING HEALTHY ADULTS OR THOSE AT HIGH RISK OF CVD. TRIALS EXAMINED ANY TYPE OF YOGA AND THE COMPARISON GROUP WAS NO INTERVENTION OR MINIMAL INTERVENTION. OUTCOMES OF INTEREST WERE CLINICAL CVD EVENTS AND MAJOR CVD RISK FACTORS. WE DID NOT INCLUDE ANY TRIALS THAT INVOLVED MULTIFACTORIAL LIFESTYLE INTERVENTIONS OR WEIGHT LOSS. DATA COLLECTION AND ANALYSIS: TWO AUTHORS INDEPENDENTLY SELECTED TRIALS FOR INCLUSION, EXTRACTED DATA AND ASSESSED THE RISK OF BIAS. MAIN RESULTS: WE IDENTIFIED 11 TRIALS (800 PARTICIPANTS) AND TWO ONGOING STUDIES. STYLE AND DURATION OF YOGA DIFFERED BETWEEN TRIALS. HALF OF THE PARTICIPANTS RECRUITED TO THE STUDIES WERE AT HIGH RISK OF CVD. MOST OF STUDIES WERE AT RISK OF PERFORMANCE BIAS, WITH INADEQUATE DETAILS REPORTED IN MANY OF THEM TO JUDGE THE RISK OF SELECTION BIAS.NO STUDY REPORTED CARDIOVASCULAR MORTALITY, ALL-CAUSE MORTALITY OR NON-FATAL EVENTS, AND MOST STUDIES WERE SMALL AND SHORT-TERM. THERE WAS SUBSTANTIAL HETEROGENEITY BETWEEN STUDIES MAKING IT IMPOSSIBLE TO COMBINE STUDIES STATISTICALLY FOR SYSTOLIC BLOOD PRESSURE AND TOTAL CHOLESTEROL. YOGA WAS FOUND TO PRODUCE REDUCTIONS IN DIASTOLIC BLOOD PRESSURE (MEAN DIFFERENCE (MD) -2.90 MMHG, 95% CONFIDENCE INTERVAL (CI) -4.52 TO -1.28), WHICH WAS STABLE ON SENSITIVITY ANALYSIS, TRIGLYCERIDES (MD -0.27 MMOL/L, 95% CI -0.44 TO -0.11) AND HIGH-DENSITY LIPOPROTEIN (HDL) CHOLESTEROL (MD 0.08 MMOL/L, 95% CI 0.02 TO 0.14). HOWEVER, THE CONTRIBUTING STUDIES WERE SMALL, SHORT-TERM AND AT UNCLEAR OR HIGH RISK OF BIAS. THERE WAS NO CLEAR EVIDENCE OF A DIFFERENCE BETWEEN GROUPS FOR LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL (MD -0.09 MMOL/L, 95% CI -0.48 TO 0.30), ALTHOUGH THERE WAS MODERATE STATISTICAL HETEROGENEITY. ADVERSE EVENTS, OCCURRENCE OF TYPE 2 DIABETES AND COSTS WERE NOT REPORTED IN ANY OF THE INCLUDED STUDIES. QUALITY OF LIFE WAS MEASURED IN THREE TRIALS BUT THE RESULTS WERE INCONCLUSIVE. AUTHORS' CONCLUSIONS: THE LIMITED EVIDENCE COMES FROM SMALL, SHORT-TERM, LOW-QUALITY STUDIES. THERE IS SOME EVIDENCE THAT YOGA HAS FAVOURABLE EFFECTS ON DIASTOLIC BLOOD PRESSURE, HDL CHOLESTEROL AND TRIGLYCERIDES, AND UNCERTAIN EFFECTS ON LDL CHOLESTEROL. THESE RESULTS SHOULD BE CONSIDERED AS EXPLORATORY AND INTERPRETED WITH CAUTION. 2014